Drug Approval | December 20, 2022
Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers
Positive opinions based on significant survival benefit
Positive opinions based on significant survival benefit
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
The product is backed by required scientific proof and comparative bioequivalence studies
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
The current ruling will assure the safety of the use of Ranitidine for Indian patients
The yoga protocol included gentle and restorative yoga postures(asana) with regular periods of relaxation and pranayama
Approval broadens indication for ENHERTU to earlier use in metastatic breast cancer and requirement for confirmatory phase 3 trial
The only definitive way to diagnose and stage lung cancers is through biopsies
Timely screening and accurate detection through precision diagnostics, targeted therapy, risk reducing surgeries, and comprehensive multimodality treatment options have resulted in improving survival rates and quality of life in cancer patients in India
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
Subscribe To Our Newsletter & Stay Updated
